http://www.insmed.com/default.aspx2013-04-18T13:05:15.8848161-04:00http://www.insmed.com/default.aspx2013-04-18T13:05:15.8848161-04:00http://www.insmed.com/about-us/overview2013-03-20T10:59:00.0000000-04:00http://www.insmed.com/about-us/management2013-04-05T07:47:00.0000000-04:00http://www.insmed.com/about-us/board-of-directors2013-02-12T08:12:00.0000000-05:00http://www.insmed.com/about-us/mission-values2012-11-15T14:47:00.0000000-05:00http://www.insmed.com/about-us/careers2012-11-15T14:47:00.0000000-05:00http://www.insmed.com/about-us/careers/open-positions2013-04-17T15:52:00.0000000-04:00http://www.insmed.com/about-us/careers.aspx2013-04-18T12:23:00.0000000-04:00http://www.insmed.com/about-us/contact-us.aspx2013-04-18T12:22:00.0000000-04:00http://www.insmed.com/product-candidates/about-arikace2013-03-20T17:19:00.0000000-04:00http://www.insmed.com/product-candidates/arikace-for-cf-patients-with-pseudomonas-lung-infections2013-03-20T17:19:00.0000000-04:00http://www.insmed.com/product-candidates/arikace-for-patients-with-ntm-lung-infections2013-03-28T08:46:00.0000000-04:00http://www.insmed.com/product-candidates/arikace-for-non-cf-bronchiectasis-patients-with-pseudomonas-lung-infections2013-03-11T12:23:00.0000000-04:00http://www.insmed.com/product-candidates/publications-and-presentations2012-11-27T16:46:00.0000000-05:00http://www.insmed.com/product-candidates/proprietary-liposomal-technology2013-03-20T11:38:00.0000000-04:00http://www.insmed.com/patient-resource-center/overview2012-11-15T14:49:00.0000000-05:00http://www.insmed.com/patient-resource-center/resources-for-cf-patients-with-pseudomonas-lung-infections2012-11-21T08:45:00.0000000-05:00http://www.insmed.com/patient-resource-center/resources-for-ntm-lung-infection-patients2012-11-20T15:51:00.0000000-05:00http://www.insmed.com/newsroom/overview2013-03-05T15:59:00.0000000-05:00http://www.insmed.com/newsroom/prior-announcements/3-31-2008-study-confirms-anti-infective-arikace--effectively-penetrates-mucus-and-biofilm-and-kills-pseudomonas-a-bacteria-plaguing-cystic-fibrosis-patients2013-03-05T15:59:00.0000000-05:00http://www.insmed.com/newsroom/prior-announcements/3-31-2008-transave-inc--raises--35-million-through-series-d-convertible-preferred-stock-financing2013-03-05T15:59:00.0000000-05:00http://www.insmed.com/newsroom/prior-announcements/6-13-2008-transave-announces-positive-phase-ii-results-for-once-daily-arikace--in-the-treatment-of-cystic-fibrosis-patients-who-have-pseudomonas-lung-infections2013-03-05T15:59:00.0000000-05:00http://www.insmed.com/newsroom/prior-announcements/10-2-2008-transave-inc--secures--12-5-million-in-new-financing-strength-of-phase-ii-data-for-lead-drug-candidate-arikace--drives-continued-clinical-expansion2013-03-05T15:59:00.0000000-05:00http://www.insmed.com/newsroom/prior-announcements/4-21-2009-transave-completes-enrollment-in-arikace--phase-ii-bronchietctasis-study2013-03-05T15:59:00.0000000-05:00http://www.insmed.com/newsroom/prior-announcements/6-25-2009-transave-receives--2-2-million-cystic-fibrosis-foundation-award-for-development-of-arikace2013-03-05T15:59:00.0000000-05:00http://www.insmed.com/newsroom/prior-announcements/7-30-2009-transave-enters-into-cooperative-research-agreement-with-nih-to-study-arikace--in-nontuberculosis-mycobacteria2013-03-05T15:59:00.0000000-05:00http://www.insmed.com/newsroom/prior-announcements/9-13-2009-transave-announces-positive-phase-ii-results-for-once-daily-arikace--in-the-treatment-of-non-bronchiectasis-patients-who-have-pseudonomas-lung-infections2013-03-05T15:59:00.0000000-05:00http://www.insmed.com/newsroom/prior-announcements/10-17-2009-transave-completes-successful-phase-ii-clinical-program-for-arikace--in-the-treatment-of-pseudomonas-lung-infections2013-03-05T15:59:00.0000000-05:00http://www.insmed.com/newsroom/prior-announcements/5-24-2010-transave-issued-key-composition-of-matter-for-arikace2013-03-05T15:59:00.0000000-05:00http://www.insmed.com/newsroom/prior-announcements/6-17-2010-arikace--demonstrates-sustained-benefit-in-the-treatment-of-scystic-fibrosis-in-patients-who-have-pseudomonas-lung-infections2013-03-05T15:59:00.0000000-05:00http://www.insmed.com/newsroom/prior-announcements/10-21-2010-arikace--demonstrates-sustained-benefit-in-multiple-studies-and-over-multiple-cycles-of-treatment-of-pseudomonas-lung-infections-in-cystic-fibrosis-patients2013-03-05T15:59:00.0000000-05:00http://www.insmed.com/newsroom/prior-announcements/12-2-2010-insmed-incorporated-and-transave-inc--announce-business-combination2013-03-05T15:59:00.0000000-05:00http://www.insmed.com/newsroom/media-resources2012-11-15T14:39:00.0000000-05:00